Discontinuation of biologic therapy in patients with rheumatoid arthritis and ankylosing spondylitis: analysis from multicenter cohort studyN. El Ouardi, A. Bezza, A. El Maghraoui et al.|Rheumatology International|2022Cited by 11
One-year direct costs of biological therapy in rheumatoid arthritis and its predictive factors: data from the Moroccan RBSMR registryS. Fellous, F. Allali, Hanan Rkain et al.|Rheumatology International|2021Cited by 10
Prevalence of latent tuberculosis before biotherapy initiation in rheumatoid arthritis and spondyloarthritis: data from the Moroccan biotherapy registryLamia Oulkadi, R. Bahiri, S. Rostom et al.|Rheumatology International|2021Cited by 9
Extra-Articular Manifestations in Patients with Ankylosing Spondylitis: Baseline Characteristics from the RBSMR StudyN. El Ouardi, L. Achemlal, Julien Djossou et al.|Mediterranean Journal of Rheumatology|2022Cited by 8
Radiographic axial versus nonradiographic axial spondyloarthritis: Comparison of the disease activity parameters and the disease activity and functional scores: RBSMR studyS Bencherifa, Niamane R Bahiri R, El Bouchti et al.|International Journal of Clinical Rheumatology|2019Cited by 7